Inotiv | analyze. answer. advance.
  • About
    • Why Inotiv
    • Leadership
    • News
    • Events
    • Regulatory Compliance
    • Our Commitment to Integrity and Ethical Conduct
  • Services
    • Research and Discovery
      • Computational Toxicology
      • Disease Pharmacology (in vitro and in vivo)
      • DMPK (in vitro and in vivo)
      • Safety Pharmacology
      • Cell and Molecular Biology
      • Discovery Bioanalysis
        • Biomarkers
      • Exploratory Toxicology
        • Toxicogenomics
        • Genetic Toxicology
        • General Toxicology
      • Surgical Models and Medical Device
    • Nonclinical Safety Assessment
      • General Toxicology
      • Safety Pharmacology
      • Genetic Toxicology
      • Regulated Bioanalysis
      • — Biotherapeutics
        • Biomarker
      • DMPK (PK/TK)
      • Developmental and Reproductive Toxicology
      • Carcinogenicity Studies
      • Surgical Models and Medical Device
    • Pathology
      • Histology
      • Digital Pathology
      • Clinical Pathology
      • Medical Device Pathology
    • Bioanalysis
      • Nonregulated Discovery Bioanalysis
      • Regulated Preclinical and Clinical Bioanalysis
      • Biotherapeutics
        • Biomarkers
    • Proteomics
    • Consulting
    • Research Models and Services
  • Insights
  • Contact
  • |
  • Investors
  • Careers
  • VISIT OUR VIRTUAL BOOTH

Leadership

A Team as Committed as You Are

Our team expects you to expect more

At Inotiv, we’re committed to supporting your discovery and development objectives and helping you realize the full potential of your critical R&D projects, all while working together to build a healthier and safer world.

Robert Leasure Jr.

Chief Executive Officer, President, and Director

Greg Beattie

Chief Operating Officer, DSA

Beth A. Taylor, CPA

Senior Vice President of Finance and Chief Financial Officer

Mike Garrett, M.S.

Chief Commercial Officer

Mo Dastagir

Chief Technology Officer

William D. Pitchford

Chief Human Resources Officer

John Sagartz, DVM, PhD, DACVP

Chief Strategy Officer
and Director

Fernanda Beraldi

General Counsel and Corporate Secretary

Adrian Hardy, Ph.D.

Executive Vice President

Lizanne Muller

Group President, RMS

Glenn Washer

Group President, Safety Assessment
Get the Insights You Deserve

Answering the right questions on time and with high-quality data is the key to achieving your objectives. Expect more.

Get In Touch
Inotiv Logo

2701 Kent Avenue
West Lafayette, IN 47906 USA
800.845.4246
765.463.4527

Copyright © 2023 Inotiv. All Rights Reserved.

  • Privacy
  • Accessibility
  • Terms Of Use
  • Contact
  • About
    • Why Inotiv
    • Leadership
    • News
    • Events
    • Regulatory Compliance
    • Our Commitment to Integrity and Ethical Conduct
  • Services
    • Research and Discovery
      • Computational Toxicology
      • Disease Pharmacology (in vitro and in vivo)
      • DMPK (in vitro and in vivo)
      • Safety Pharmacology
      • Cell and Molecular Biology
      • Discovery Bioanalysis
        • Biomarkers
      • Exploratory Toxicology
        • Toxicogenomics
        • Genetic Toxicology
        • General Toxicology
      • Surgical Models and Medical Device
    • Nonclinical Safety Assessment
      • General Toxicology
      • Safety Pharmacology
      • Genetic Toxicology
      • Regulated Bioanalysis
      • — Biotherapeutics
        • Biomarker
      • DMPK (PK/TK)
      • Developmental and Reproductive Toxicology
      • Carcinogenicity Studies
      • Surgical Models and Medical Device
    • Pathology
      • Histology
      • Digital Pathology
      • Clinical Pathology
      • Medical Device Pathology
    • Bioanalysis
      • Nonregulated Discovery Bioanalysis
      • Regulated Preclinical and Clinical Bioanalysis
      • Biotherapeutics
        • Biomarkers
    • Proteomics
    • Consulting
    • Research Models and Services
  • Insights
  • Contact
  • |
  • Investors
  • Careers
  • VISIT OUR VIRTUAL BOOTH